Cargando…

Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery

BACKGROUND: The poor prognosis of patients who experience ipsilateral breast tumor recurrence (IBTR) after breast conserving surgery (BCS) is established. A short time between primary cancer and IBTR is a prognostic factor but no clinically relevant threshold was determined. Classification of IBTR m...

Descripción completa

Detalles Bibliográficos
Autores principales: Gosset, Marie, Hamy, Anne-Sophie, Mallon, Peter, Delomenie, Myriam, Mouttet, Delphine, Pierga, Jean-Yves, Lae, Marick, Fourquet, Alain, Rouzier, Roman, Reyal, Fabien, Feron, Jean-Guillaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975471/
https://www.ncbi.nlm.nih.gov/pubmed/27494111
http://dx.doi.org/10.1371/journal.pone.0159888
_version_ 1782446733363511296
author Gosset, Marie
Hamy, Anne-Sophie
Mallon, Peter
Delomenie, Myriam
Mouttet, Delphine
Pierga, Jean-Yves
Lae, Marick
Fourquet, Alain
Rouzier, Roman
Reyal, Fabien
Feron, Jean-Guillaume
author_facet Gosset, Marie
Hamy, Anne-Sophie
Mallon, Peter
Delomenie, Myriam
Mouttet, Delphine
Pierga, Jean-Yves
Lae, Marick
Fourquet, Alain
Rouzier, Roman
Reyal, Fabien
Feron, Jean-Guillaume
author_sort Gosset, Marie
collection PubMed
description BACKGROUND: The poor prognosis of patients who experience ipsilateral breast tumor recurrence (IBTR) after breast conserving surgery (BCS) is established. A short time between primary cancer and IBTR is a prognostic factor but no clinically relevant threshold was determined. Classification of IBTR may help tailor treatment strategies. PURPOSE: We determined a specific time frame, which differentiates IBTR into early and late recurrence, and identified prognostic factors for patients with IBTR at time of the recurrence. METHODS: We analyzed 2209 patients with IBTR after BCS. We applied the optimal cut-points method for survival data to determine the cut-off times to IBTR. A subgroup analysis was performed by hormone receptor (HR) status. Survival analyses were performed using a Cox proportional hazard model to determine clinical features associated with distant-disease-free survival (DDFS) after IBTR. We therefor built decision trees. RESULTS: On the 828 metastatic events observed, the majority occurred within the first 3 months after IBTR: 157 in the HR positive group, 98 in the HR negative group. We found different prognostic times to IBTR: 49 months in the HR positive group, 33 in the HR negative group. After multivariate analysis, time to IBTR was the first discriminant prognostic factor in both groups (HR 0.65 CI95% [0.54–0.79] and 0.42 [0.30–0.57] respectively). The other following variables were significantly correlated with the DDFS: the initial number of positive lymph nodes for both groups, the initial tumor size and grade for HR positive tumors. CONCLUSION: A short interval time to IBTR is the strongest factor of poor prognosis and reflects occult distant disease. It would appear that prognosis after IBTR depends more on clinical and histological parameters than on surgical treatment. A prospective trial in a low-risk group of patients to validate the safety of salvage BCS instead of mastectomy in IBTR is needed.
format Online
Article
Text
id pubmed-4975471
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49754712016-08-25 Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery Gosset, Marie Hamy, Anne-Sophie Mallon, Peter Delomenie, Myriam Mouttet, Delphine Pierga, Jean-Yves Lae, Marick Fourquet, Alain Rouzier, Roman Reyal, Fabien Feron, Jean-Guillaume PLoS One Research Article BACKGROUND: The poor prognosis of patients who experience ipsilateral breast tumor recurrence (IBTR) after breast conserving surgery (BCS) is established. A short time between primary cancer and IBTR is a prognostic factor but no clinically relevant threshold was determined. Classification of IBTR may help tailor treatment strategies. PURPOSE: We determined a specific time frame, which differentiates IBTR into early and late recurrence, and identified prognostic factors for patients with IBTR at time of the recurrence. METHODS: We analyzed 2209 patients with IBTR after BCS. We applied the optimal cut-points method for survival data to determine the cut-off times to IBTR. A subgroup analysis was performed by hormone receptor (HR) status. Survival analyses were performed using a Cox proportional hazard model to determine clinical features associated with distant-disease-free survival (DDFS) after IBTR. We therefor built decision trees. RESULTS: On the 828 metastatic events observed, the majority occurred within the first 3 months after IBTR: 157 in the HR positive group, 98 in the HR negative group. We found different prognostic times to IBTR: 49 months in the HR positive group, 33 in the HR negative group. After multivariate analysis, time to IBTR was the first discriminant prognostic factor in both groups (HR 0.65 CI95% [0.54–0.79] and 0.42 [0.30–0.57] respectively). The other following variables were significantly correlated with the DDFS: the initial number of positive lymph nodes for both groups, the initial tumor size and grade for HR positive tumors. CONCLUSION: A short interval time to IBTR is the strongest factor of poor prognosis and reflects occult distant disease. It would appear that prognosis after IBTR depends more on clinical and histological parameters than on surgical treatment. A prospective trial in a low-risk group of patients to validate the safety of salvage BCS instead of mastectomy in IBTR is needed. Public Library of Science 2016-08-05 /pmc/articles/PMC4975471/ /pubmed/27494111 http://dx.doi.org/10.1371/journal.pone.0159888 Text en © 2016 Gosset et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Gosset, Marie
Hamy, Anne-Sophie
Mallon, Peter
Delomenie, Myriam
Mouttet, Delphine
Pierga, Jean-Yves
Lae, Marick
Fourquet, Alain
Rouzier, Roman
Reyal, Fabien
Feron, Jean-Guillaume
Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery
title Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery
title_full Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery
title_fullStr Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery
title_full_unstemmed Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery
title_short Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery
title_sort prognostic impact of time to ipsilateral breast tumor recurrence after breast conserving surgery
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975471/
https://www.ncbi.nlm.nih.gov/pubmed/27494111
http://dx.doi.org/10.1371/journal.pone.0159888
work_keys_str_mv AT gossetmarie prognosticimpactoftimetoipsilateralbreasttumorrecurrenceafterbreastconservingsurgery
AT hamyannesophie prognosticimpactoftimetoipsilateralbreasttumorrecurrenceafterbreastconservingsurgery
AT mallonpeter prognosticimpactoftimetoipsilateralbreasttumorrecurrenceafterbreastconservingsurgery
AT delomeniemyriam prognosticimpactoftimetoipsilateralbreasttumorrecurrenceafterbreastconservingsurgery
AT mouttetdelphine prognosticimpactoftimetoipsilateralbreasttumorrecurrenceafterbreastconservingsurgery
AT piergajeanyves prognosticimpactoftimetoipsilateralbreasttumorrecurrenceafterbreastconservingsurgery
AT laemarick prognosticimpactoftimetoipsilateralbreasttumorrecurrenceafterbreastconservingsurgery
AT fourquetalain prognosticimpactoftimetoipsilateralbreasttumorrecurrenceafterbreastconservingsurgery
AT rouzierroman prognosticimpactoftimetoipsilateralbreasttumorrecurrenceafterbreastconservingsurgery
AT reyalfabien prognosticimpactoftimetoipsilateralbreasttumorrecurrenceafterbreastconservingsurgery
AT feronjeanguillaume prognosticimpactoftimetoipsilateralbreasttumorrecurrenceafterbreastconservingsurgery